Results 181 to 190 of about 44,698 (259)

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, EarlyView.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source

Immune regulatory mechanisms in the tumor microenvironment and their applications in cancer therapy: from basic research to clinical translation. [PDF]

Front Immunol
Feng Y, Wang Y, Li X, Wang Y, Zhang M.
europepmc   +1 more source

Visualization of Scattered Tumor Regression Following Neoadjuvant Chemoimmunotherapy With a Novel Intraoperative PET/CT Scanner

Head &Neck, EarlyView.
ABSTRACT Background Neoadjuvant chemoimmunotherapy is being explored in locally advanced head and neck squamous cell carcinoma (HNSCC), yet the spatial patterns of pathologic response and clinical implications remain poorly characterized. Methods A 79‐year‐old female with recurrent left oral tongue SCC (PD‐L122C3 Combined Positive Score 90) who ...
Andreja Radevic, Joaquin Austerlitz, Ashtyn McAdoo, Kyrionna Golliday, Takeshi Takahashi, Mitra Mehrad, Adam J. Rosenberg, Barbara A. Murphy, Eben Rosenthal, Michael C. Topf   +9 more
wiley   +1 more source

Immunotherapy in Thyroid Cancer: Current Strategies and Challenges. [PDF]

Cancer Med
Zhang Q, Wang F, Ma W, Liu N, Lu Y, Zhang P.   +5 more
europepmc   +1 more source

Non‐Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

Head &Neck, EarlyView.
ABSTRACT Background In patients with locally advanced, non‐metastatic oropharyngeal squamous cell carcinoma (OPSCC), surgery‐based and nonsurgical treatment approaches have not been adequately compared in randomized Phase III clinical trials. Current clinical guidelines recommend various surgical and nonsurgical strategies across disease stages for ...
Primož Strojan, Avraham Eisbruch, June Corry, Sandra Nuyts, Pim de Graaf, Luiz P. Kowalski, Jonathan J. Beitler, Sweet Ping Ng, William M. Mendenhall, M. P. Sreeram, Karthik N. Rao, Anna Luíza Damaceno Araújo, Alfio Ferlito   +12 more
wiley   +1 more source

Myeloid-Derived Suppressor Cells: Function, Migration, and Therapeutic Opportunities in Glioblastoma. [PDF]

Cells
Figg JW, Love C, West I, Jin D, Engelbart M, Ware D, Bessey R, Flores CT.   +7 more
europepmc   +1 more source

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Head &Neck, EarlyView.
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley   +1 more source

Advances in natural killer cell immunotherapy for hematologic malignancies. [PDF]

Cancer Biol Ther
Hu H, Xiong Y, Xia M, Sheng L.
europepmc   +1 more source

Nanotechnology-Assisted Co-Delivery of Immunotherapeutic Agents for Targeting Ovarian Cancer: Prospects and Challenges. [PDF]

Int J Nanomedicine
Jiao L, Li M, Tan M, Zheng L, Liu Y, Cao Y.   +5 more
europepmc   +1 more source

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source